20 min listen
Reducing Microbial Contamination Risk with Anthony Repay, M.S.
Reducing Microbial Contamination Risk with Anthony Repay, M.S.
ratings:
Length:
35 minutes
Released:
Mar 29, 2023
Format:
Podcast episode
Description
Anthony Repay is currently serving as Laboratory Director of Method Testing Laboratories in Tampa, FL. Anthony started his career as the head food and environmental microbiologist at a Chicago-based testing laboratory before joining the cannabis science community. Since joining cannabis, Anthony has tried to innovate and push the cannabis microbiology community by publishing peer-reviewed papers, speaking on proper quality control and volunteering in several national wide cannabis groups.
During our conversation we discuss:
How growers can incorporate microbial testing into their processes Sources of microbial contamination and tips for prevention How differences in microbial regulations influence growers in certain states Remediation technologies and more
Thanks to This Episode's Sponsor: RS BioTherapeutics
RS BioTherapeutics’ first investigational compound (RSBT-001) is a nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. More information on RS BioTherapeutics can be found at www.rsbiotherapeutics.com.
Additional Resources
Anthony Repay on LinkedInMethod Testing Laboratories websiteCannabis Microbial Testing Regulations by State [Interactive Tool]Request an Invitation to CannMed 23Review the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]Healthcare Provider Medical Cannabis Research Study
During our conversation we discuss:
How growers can incorporate microbial testing into their processes Sources of microbial contamination and tips for prevention How differences in microbial regulations influence growers in certain states Remediation technologies and more
Thanks to This Episode's Sponsor: RS BioTherapeutics
RS BioTherapeutics’ first investigational compound (RSBT-001) is a nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. More information on RS BioTherapeutics can be found at www.rsbiotherapeutics.com.
Additional Resources
Anthony Repay on LinkedInMethod Testing Laboratories websiteCannabis Microbial Testing Regulations by State [Interactive Tool]Request an Invitation to CannMed 23Review the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]Healthcare Provider Medical Cannabis Research Study
Released:
Mar 29, 2023
Format:
Podcast episode
Titles in the series (96)
Endocannabinoid System Deep Dive with Mauro Maccarrone, PhD: Our guest in this episode is Dr. Mauro Maccarrone. Mauro is a pioneer in endocannabinoid research. In 1997, his team identified the receptor targets for the first two endocannabinoids that were discovered by Professor Raphael Mechoulam earlier in the d... by CannMed Coffee Talk